Advertisement
Singapore markets close in 2 hours 34 minutes

  • Straits Times Index

    3,285.13
    -2.62 (-0.08%)
     

  • Nikkei

    37,934.76
    +306.28 (+0.81%)
     

  • Hang Seng

    17,704.67
    +420.13 (+2.43%)
     

  • FTSE 100

    8,078.86
    +38.48 (+0.48%)
     

  • Bitcoin USD

    64,428.68
    +145.83 (+0.23%)
     

  • CMC Crypto 200

    1,391.98
    -4.56 (-0.33%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • Dow

    38,085.80
    -375.12 (-0.98%)
     

  • Nasdaq

    15,611.76
    -100.99 (-0.64%)
     

  • Gold

    2,349.80
    +7.30 (+0.31%)
     

  • Crude Oil

    83.99
    +0.42 (+0.50%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • FTSE Bursa Malaysia

    1,573.86
    +4.61 (+0.29%)
     

  • Jakarta Composite Index

    7,115.99
    -39.31 (-0.55%)
     

  • PSE Index

    6,592.27
    +17.39 (+0.26%)
     

Why NRx Pharmaceuticals Stock Soared Today

Joe Tenebruso, The Motley Fool
·1-min read
Why NRx Pharmaceuticals Stock Soared Today

Shares of NRx Pharmaceuticals (NASDAQ: NRXP) surged on Monday after the healthcare company released promising clinical trial data for its investigational COVID-19 treatment, aviptadil. An analysis conducted by respected statistician Dr. David Schoenfeld found that patients treated with aviptadil had a significantly higher probability of recovering from critical COVID-19 and respiratory failure than those who received existing therapies. Among those who previously received Gilead Sciences' (NASDAQ: GILD) remdesivir, patients treated with aviptadil were 2.5 times more likely to be alive and free of respiratory failure at 60 days than those who received a placebo.

Continue reading